These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. What is the success of drug treatment in urge urinary incontinence? What should be measured? Dede H; Dolen İ; Dede FS; Sivaslioglu AA Arch Gynecol Obstet; 2013 Mar; 287(3):511-8. PubMed ID: 23086134 [TBL] [Abstract][Full Text] [Related]
5. Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan. D'Souza AO; Smith MJ; Miller LA; Doyle J; Ariely R J Manag Care Pharm; 2008 Apr; 14(3):291-301. PubMed ID: 18439051 [TBL] [Abstract][Full Text] [Related]
6. [Comparisons of efficacy and safety of tolterodine and oxybutynin in children with idiopathic overactive bladder]. Deng YJ; Ma G; Guo YF; Ge Z; Lu RG; Wang LX; Zhu HB; Chen CJ Zhongguo Dang Dai Er Ke Za Zhi; 2011 Jan; 13(1):26-8. PubMed ID: 21251382 [TBL] [Abstract][Full Text] [Related]
7. Trospium chloride in the management of overactive bladder. Rovner ES Drugs; 2004; 64(21):2433-46. PubMed ID: 15482001 [TBL] [Abstract][Full Text] [Related]
8. Update on drugs for overactive bladder syndrome. Drug Ther Bull; 2007 Jun; 45(6):44-8. PubMed ID: 17583229 [TBL] [Abstract][Full Text] [Related]
9. Treatment of the overactive bladder syndrome with muscarinic receptor antagonists: a matter of metabolites? Michel MC; Hegde SS Naunyn Schmiedebergs Arch Pharmacol; 2006 Nov; 374(2):79-85. PubMed ID: 17021853 [TBL] [Abstract][Full Text] [Related]
10. Comparison of tolterodine with standard treatment in pediatric patients with non-neurogenic dysfunctional voiding/over active bladder: a systematic review. Medhi B; Mittal N; Bansal D; Prakash A; Sarangi SC; Nirthi B Indian J Physiol Pharmacol; 2013; 57(4):343-53. PubMed ID: 24968572 [TBL] [Abstract][Full Text] [Related]
11. Tolterodine for treatment of overactive bladder. Kanofsky JA; Nitti VW Urol Clin North Am; 2006 Nov; 33(4):447-53, viii. PubMed ID: 17011380 [TBL] [Abstract][Full Text] [Related]
15. Retrospective evaluation of outcomes in patients with overactive bladder receiving tolterodine versus oxybutynin. Jumadilova Z; Varadharajan S; Girase P; Ollendorf DA Am J Health Syst Pharm; 2006 Dec; 63(23):2357-64. PubMed ID: 17106009 [TBL] [Abstract][Full Text] [Related]
16. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service. Cardozo L; Thorpe A; Warner J; Sidhu M BJU Int; 2010 Aug; 106(4):506-14. PubMed ID: 20132203 [TBL] [Abstract][Full Text] [Related]
17. Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the antimuscarinic clinical effectiveness trial (ACET). Sussman D; Garely A Curr Med Res Opin; 2002; 18(4):177-84. PubMed ID: 12201616 [TBL] [Abstract][Full Text] [Related]
18. New strategies for medical management of overactive bladder in children. Schröder A; Thüroff JW Curr Opin Urol; 2010 Jul; 20(4):313-7. PubMed ID: 21475074 [TBL] [Abstract][Full Text] [Related]
19. Treatment of overactive bladder: the Antimuscarinic Clinical Effectiveness Trial. Appell RA Curr Urol Rep; 2002 Oct; 3(5):343-4. PubMed ID: 12354340 [No Abstract] [Full Text] [Related]
20. The newer antimuscarinic drugs: bladder control with less dry mouth. Appell RA Cleve Clin J Med; 2002 Oct; 69(10):761, 765-6, 768-9. PubMed ID: 12371799 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]